Ensysce Biosciences, Inc. (ENSC)
ENSC Stock Price Chart
Explore Ensysce Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze ENSC price movements and trends.
ENSC Company Profile
Discover essential business fundamentals and corporate details for Ensysce Biosciences, Inc. (ENSC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Mar 2018
Employees
7.00
Website
https://www.ensysce.comCEO
D. Lynn Kirkpatrick
Description
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
ENSC Financial Timeline
Browse a chronological timeline of Ensysce Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.85.
Earnings released on 13 Aug 2025
EPS came in at -$0.79 surpassing the estimated -$1.02 by +22.55%, while revenue for the quarter reached $1.37M , missing expectations by -1.96%.
Earnings released on 13 May 2025
EPS came in at -$1.39 surpassing the estimated -$3.02 by +53.97%, while revenue for the quarter reached $1.32M .
Earnings released on 10 Mar 2025
EPS came in at -$2.90 falling short of the estimated -$2.74 by -5.84%, while revenue for the quarter reached $1.30M , beating expectations by +432.24%.
Stock split effective on 6 Dec 2024
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Nov 2024
EPS came in at $1.05 surpassing the estimated -$4.50 by +123.33%, while revenue for the quarter reached $3.42M , beating expectations by +1.30K%.
Earnings released on 14 Aug 2024
EPS came in at -$3.30 surpassing the estimated -$5.85 by +43.59%, while revenue for the quarter reached $181.80K , missing expectations by -39.40%.
Earnings released on 10 May 2024
EPS came in at -$8.25 surpassing the estimated -$13.49 by +38.84%, while revenue for the quarter reached $305.72K , missing expectations by -23.57%.
Earnings released on 15 Mar 2024
EPS came in at -$16.94 falling short of the estimated -$12.89 by -31.42%, while revenue for the quarter reached $515.03K , beating expectations by +106.01%.
Earnings released on 9 Nov 2023
EPS came in at -$13.04 surpassing the estimated -$15.89 by +17.94%, while revenue for the quarter reached $435.38K , beating expectations by +11.64%.
Earnings released on 11 Aug 2023
EPS came in at -$14.69 surpassing the estimated -$40.93 by +64.11%, while revenue for the quarter reached $490.47K , missing expectations by -40.91%.
Earnings released on 15 May 2023
EPS came in at -$31.18 surpassing the estimated -$208.55 by +85.05%, while revenue for the quarter reached $789.64K , missing expectations by -16.88%.
Stock split effective on 31 Mar 2023
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Mar 2023
EPS came in at -$273.57 surpassing the estimated -$466.15 by +41.31%, while revenue for the quarter reached $1.43M , beating expectations by +49.27%.
Earnings released on 14 Nov 2022
EPS came in at -$923.31 falling short of the estimated -$539.95 by -71.00%, while revenue for the quarter reached $279.35K , missing expectations by -81.86%.
Stock split effective on 28 Oct 2022
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Aug 2022
EPS came in at -$863.91 falling short of the estimated -$755.92 by -14.29%, while revenue for the quarter reached $207.47K , missing expectations by -79.25%.
Earnings released on 12 May 2022
EPS came in at -$719.93 matching the estimated -$719.93, while revenue for the quarter reached $603.10K , missing expectations by -49.74%.
Earnings released on 31 Mar 2022
EPS came in at -$1.62K falling short of the estimated $323.97 by -600.00%, while revenue for the quarter reached $1.64M , beating expectations by +104.38%.
Earnings released on 15 Nov 2021
EPS came in at -$2.56K , while revenue for the quarter reached $1.20M .
Earnings released on 16 Aug 2021
EPS came in at -$215.98 , while revenue for the quarter reached $444.52K .
Earnings released on 8 Jun 2021
EPS came in at -$8.98 , while revenue for the quarter reached $250.58K .
Earnings released on 15 Mar 2021
EPS came in at $0.03 , while revenue for the quarter reached $416.49K .
Earnings released on 9 Nov 2020
EPS came in at $15.53 , while revenue for the quarter reached $827.64K .
ENSC Stock Performance
Access detailed ENSC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.